Media

Corgentech to Present at Deutsche Bank's 29th Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif., Apr 30, 2004 /PRNewswire-FirstCall via COMTEX/ -- Corgentech Inc. (Nasdaq: CGTK), a biotechnology company, today announced that John McLaughlin, the company's president and chief executive officer, will present at Deutsche Bank's 29th Annual Health Care Conference. The five-minute presentation, followed by a 20-minute question-and-answer session, will be held on Tuesday, May 4 at 11 a.m. EDT, in the Homeland Room at the Renaissance Harborplace Hotel in Baltimore.

McLaughlin will discuss the company's progress with its lead product candidate, a novel and proprietary transcription factor decoy, known as E2F Decoy (edifoligide sodium), which currently is in two Phase 3 clinical trials: one in coronary artery bypass graft (CABG) surgery, the other in peripheral (i.e., in the leg) bypass graft surgery, for the single indication of prevention of bypass graft failure. He also will describe a planned Phase 1/2 clinical trial with E2F Decoy for arterio-venous (AV) graft failure in end-stage renal disease patients who require hemodialysis. Both indications have FDA Fast Track Status. Finally, McLaughlin will address other projects in the company's expanding pipeline based on its novel and versatile research platform.

To access the live audio webcast or the subsequent archived recording, log on to www.corgentech.com and go to the Investor Information page. Please connect to Corgentech's website several minutes prior to the start of the conference call to ensure adequate time for any software download that may be necessary.

About Corgentech

Corgentech is a biopharmaceutical company engaged in the discovery, development and commercialization of a new class of therapeutics called transcription factor decoys, or TF decoys. We are creating a pipeline of novel therapeutics based on our proprietary TF decoy technology, focused initially on the treatment of cardiovascular disease, inflammatory disease and cancer. For more information on the company and its technology, visit www.corgentech.com.

Forward-Looking Statements

This press release contains forward-looking statements, including without limitation all statements related to our clinical trials and product candidates. Words such as "believes," "anticipates," "plans," "expects," "intend," "will," "slated," "goal" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon our current expectations. Forward-looking statements involve risks and uncertainties. Our actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the progress, timing and results of our clinical trials, intellectual property matters, difficulties or delays in obtaining regulatory approval, manufacturing our lead product candidate, competition from other pharmaceutical or biotechnology companies, our ability to obtain additional financing to support our operations and other risks detailed in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2003. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and Corgentech undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.

SOURCE Corgentech Inc.

Richard Powers of Corgentech, +1-650-624-9600, or
[email protected]; or Kristin Nash of WeissCom Partners,
+1-415-302-7951, or [email protected]

http://www.corgentech.com

News Provided by COMTEX